BridgeBio Pharma, Inc. BBIO R2KR3KPHARMA
Company Overview
BridgeBio Pharma, Inc., a biopharmaceutical company, discovers, develops, and delivers medicines for patients with genetic diseases. The company offers Attruby, a next-generation oral small molecule near-complete TTR stabilizer for the treatment of cardiomyopathy of wild-type or transthyretin-mediated amyloidosis (ATTR-CM); Fosdenopterin, an intravenous formulation of synthetic cyclic pyranopterin monophosphate for the treatment of molybdenum cofactor deficiency under the NULIBRY brand name; and low-dose infigratinib, an oral FGFR1-3 selective tyrosine kinase inhibitor, which is in Phase 3 clinical stage or the treatment of children with achondroplasia and hypochondroplasia. It also develops Encaleret, an oral small molecule, negative allosteric modulator of the calcium sensing receptor, which is in phase 3 clinical study for the treatment of Autosomal Dominant Hypocalcemia Type 1(ADH1) and Chronic Hypoparathyroidism (CHP); BBP-418, an investigational, orally administered, and small molecule therapy that is in phase 3 clinical study for the treatment of LGMD2I; and BBP-812, an investigational adeno-associated virus (AAV) gene therapy for Canavan disease. In addition, the company engages in developing products for mendelian, oncology, and gene therapy diseases. It has license and collaboration agreements with the Bayer Consumer Care AG, Alexion Pharma International Operations Limited Company, Leland Stanford Junior University, and Novartis International Pharmaceutical Ltd. BridgeBio Pharma, Inc. was founded in 2015 and is headquartered in Palo Alto, California.
Why Investors Should Care
Generates a return on equity of 34.7%, reflecting efficient use of shareholder capital.
Revenue has grown at a 65.4% CAGR over the past five years.
Recent Developments
- Dec 2025 Revenue of $502.08M (+126.3% YoY); net profit $-724.93M.
- Trailing 12 Months Year-on-year growth — revenue +66.8%.
- 5-Year Trend Long-term compounding — revenue CAGR 65.4%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | 65.40% |
| 1 Year: | 66.80% |
Stock Price Performance
| 1 Year: | +48.55% |
| 6 Months: | +14.50% |
| 3 Months: | +10.69% |
| 1 Month: | -9.61% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMABelow
- Price vs 200-DMAAbove
- RSI (14)32.24 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- Strong return on equity of 34.7%.
- Compounding revenue at 65.4% over 5 years.
- In a confirmed uptrend (50-DMA above 200-DMA).
CONS
No notable concerns flagged.
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | BBIO BridgeBio Pharma, Inc. R2KR3KPHARMA | 74.84 | -20.01 | $14.66B | 0.00% | -77.47% | 34.74% | 65.40% | - |
| 2 | LLY Eli Lilly and Company SPXR3KPHARMA | 1,149.36 | 38.57 | $1.02T | 0.58% | - | 102.29% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPXR3KPHARMA | 275.23 | 31.97 | $663.28B | 2.09% | 14.88% | 25.74% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPXR3KPHARMA | 256.46 | 72.45 | $453.19B | 2.84% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | MRK Merck & Co., Inc. SPXR3KPHARMA | 150.33 | 120.26 | $371.29B | 2.65% | - | 34.70% | 5.64% | 10.01% |
| 6 | UNH UnitedHealth Group Incorporated SPXR3KPHARMA | 397.14 | 25.54 | $356.47B | 2.33% | 9.74% | 14.15% | 10.40% | 5.43% |
| 7 | NVS Novartis AG PHARMA | 159.99 | 24.20 | $304.10B | 3.03% | 21.09% | 30.35% | 9.25% | 26.22% |
| 8 | AZN AstraZeneca PLC NDXPHARMA | 162.70 | 24.36 | $252.33B | 1.98% | 15.97% | 21.96% | 9.82% | 45.96% |
| 9 | AMGN Amgen Inc. NDXSPXR3KPHARMA | 437.23 | 27.14 | $235.98B | 2.49% | 13.95% | 91.47% | 5.51% | 5.55% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Sep 2018 | Mar 2019 | Jun 2019 | Sep 2019 | Mar 2020 | Jun 2020 | Sep 2020 | Mar 2021 | Jun 2021 | Sep 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | 26.74M | - | - | 8.13M | 462.00K | 54.02M | 2.34M | 1.69M | 73.75M | 338.00K | 1.83M | 1.64M | 4.09M | 211.12M | 2.17M | - | - | 116.63M | 110.56M | 120.70M | 154.18M | 194.51M | 243.68M |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 2.64M | 3.65M | 6.56M | 8.11M | 9.94M | - |
| Gross Profit | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 113.99M | 106.91M | 114.14M | 146.07M | 184.58M | - |
| Operating Expenses | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 217.80M | 240.38M | 250.50M | 274.50M | 290.53M | - |
| Operating Income | -41.46M | -63.75M | -69.32M | -54.53M | -102.49M | -124.57M | -119.94M | -167.50M | -94.02M | -149.50M | -173.68M | -80.18M | -129.12M | -126.16M | -146.10M | -157.69M | 343.00K | -175.54M | - | - | -103.80M | -133.47M | -136.36M | -128.43M | -105.96M | -107.08M |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -126.18M | -142.70M | -136.94M | -143.01M | -112.55M | - |
| Interest Expense | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 42.14M | 37.64M | 48.15M | 50.31M | 52.81M | - |
| Pretax Income | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -169.61M | -181.66M | -186.48M | -194.75M | -166.56M | - |
| Tax Provision | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 2.10M | -1.54M | -120.00K | - | - |
| Net Income | -31.40M | -61.19M | -65.96M | -59.98M | -91.85M | -121.03M | -115.86M | -163.08M | -96.35M | -155.94M | -196.40M | -9.86M | -137.34M | -140.16M | -157.90M | -177.00M | -35.22M | -73.46M | - | - | -167.42M | -181.90M | -182.74M | -192.86M | -164.04M | -152.22M |
| Diluted EPS | - | - | - | - | - | - | - | - | -0.66 | -1.06 | -1.35 | -0.07 | -0.93 | -0.92 | -0.98 | -1.08 | -0.20 | -0.39 | - | - | -0.88 | -0.95 | -0.95 | -1.00 | -0.84 | -0.78 |
| R&D Expense | 31.15M | 44.85M | 52.33M | 55.28M | 68.22M | 86.60M | 92.05M | 122.56M | 101.96M | 104.31M | 107.65M | 108.40M | 92.51M | 92.86M | 107.49M | 125.14M | 140.97M | 114.69M | 120.44M | - | 111.43M | 111.23M | 112.87M | - | 126.64M | 149.45M |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | 40.56M | 8.25M | - | 77.65M | 9.30M | 221.90M | 502.08M |
| Cost of Revenue | - | - | - | - | - | 3.43M | 2.45M | 3.88M | 20.96M |
| Gross Profit | - | - | - | - | - | 74.21M | 6.86M | 218.02M | 481.11M |
| Operating Expenses | - | - | - | - | - | 542.65M | 606.30M | 795.39M | 983.18M |
| Operating Income | -43.86M | -183.66M | -266.24M | -474.48M | - | -468.44M | -599.44M | -577.37M | -502.06M |
| EBITDA | - | - | - | - | - | -397.44M | -565.47M | -436.83M | -548.83M |
| Interest Expense | - | - | - | - | - | 80.44M | 81.29M | 99.29M | 178.24M |
| Pretax Income | - | - | - | - | - | -484.65M | -653.25M | -542.19M | -732.50M |
| Tax Provision | - | - | - | - | - | 0 | 0 | 1.15M | 435.00K |
| Net Income | -30.57M | -130.75M | -260.59M | -448.72M | - | -481.18M | -643.20M | -535.76M | -724.93M |
| Diluted EPS | - | - | - | -3.80 | - | -3.26 | -3.95 | -2.88 | -3.78 |
| R&D Expense | 30.56M | 140.07M | 209.95M | 337.05M | 451.02M | 399.46M | 455.71M | 506.46M | 451.95M |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total Assets | - | - | 464.94M | 631.68M | 703.59M | - | 623.04M | 546.38M | 919.34M | 936.02M |
| Current Assets | - | - | - | - | - | - | 548.85M | 477.59M | 720.69M | 797.75M |
| Cash & Equivalents | - | 92.00M | 436.09M | 363.77M | 356.08M | - | 376.69M | 375.94M | 681.10M | 570.12M |
| Inventory | - | - | - | - | - | - | - | - | 0 | 26.75M |
| Receivables | - | - | - | - | - | - | - | 1.75M | 4.72M | 139.44M |
| Total Liabilities | - | - | 87.58M | 155.70M | 595.70M | - | 1.87B | 1.89B | 2.38B | 3.01B |
| Current Liabilities | - | - | 32.58M | 60.38M | 95.65M | - | 121.43M | 143.84M | 154.40M | 287.97M |
| Long Term Debt | - | - | 54.51M | 91.79M | 92.42M | - | 1.71B | 1.73B | 1.72B | 1.85B |
| Total Debt | - | - | - | - | - | - | 1.72B | 1.74B | 1.73B | 1.86B |
| Total Equity | 14.89M | 85.85M | 314.88M | 408.45M | 57.91M | - | -1.25B | -1.35B | -1.47B | -2.09B |
| Shares Outstanding | - | - | - | - | - | - | 156.82M | 181.27M | 196.24M | 202.37M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -40.49M | -136.64M | -253.59M | -399.71M | - | -419.49M | -527.72M | -520.73M | -445.91M |
| Investing Cash Flow | -464.00K | -21.04M | -217.25M | -52.99M | - | 453.15M | 54.03M | 60.78M | -24.49M |
| Financing Cash Flow | 112.98M | 501.55M | 398.79M | 447.19M | - | -13.13M | 451.54M | 748.46M | 359.29M |
| Capital Expenditure | -464.00K | -2.18M | -2.64M | -7.52M | - | -6.32M | -1.31M | -8.91M | -9.59M |
| Free Cash Flow | -40.95M | -138.82M | -256.23M | -407.23M | - | -425.81M | -529.03M | -529.63M | -455.50M |
| Net Change in Cash | - | - | - | - | - | 20.52M | -22.15M | 288.51M | -111.10M |
| Share Buybacks | - | - | - | 75.00M | 200.00M | 0 | 0 | 0 | 48.28M |
| Dividends Paid | 1.15M | - | 997.00K | - | - | - | - | - | - |
Ratios (Annual)
Figures in %.
| Metric | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|
| Gross Margin % | - | - | - | - | - | 95.6% | 73.7% | 98.3% | 95.8% |
| Operating Margin % | - | - | -656.4% | -5,752.0% | - | -603.3% | -6,443.6% | -260.2% | -100.0% |
| Net Margin % | - | - | -642.5% | -5,439.7% | - | -619.7% | -6,913.9% | -241.4% | -144.4% |
| ROE % | -35.6% | -41.5% | -63.8% | -774.9% | - | 38.4% | 47.5% | 36.5% | 34.7% |
| ROCE % | - | -42.5% | -46.6% | -78.0% | - | -93.4% | -148.9% | -75.5% | -77.5% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | Jupiter Topco LLC | 7.22% | 14.11M | $1.08B |
| 2 | Kohlberg Kravis Roberts & Co. L.P. | 6.78% | 13.26M | $1.02B |
| 3 | Farallon Capital Management LLC | 5.50% | 10.74M | $822.92M |
| 4 | Blackrock Inc. | 5.26% | 10.29M | $788.00M |
| 5 | Viking Global Investors, L.P. | 5.09% | 9.95M | $762.11M |
| 6 | Vanguard Capital Management LLC | 4.04% | 7.90M | $605.06M |
| 7 | Vanguard Portfolio Management LLC | 3.92% | 7.66M | $586.50M |
| 8 | Wellington Management Group, LLP | 2.72% | 5.31M | $406.66M |
| 9 | Two Sigma Investments, LP | 2.42% | 4.72M | $361.72M |
| 10 | Aisling Capital Management LP | 2.35% | 4.59M | $351.56M |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for BBIO
12 Red Days In A Row: BridgeBio Pharma Stock Is Down 11% - Trefis
<a href="https://news.google.com/rss/articles/CBMitgFBVV95cUxOU2RCcnJzcWxJNHJiMzluallEZVZVa1F0REUxQk5BWEVwQlJVRmZ6LTZSSnkyQjdoWmNYSW01TDVjTDJMTGZUZVFzTnR3ZWhxMTFjcGE3N1d5REFpZE5DNGEwZnlPRXpDbE1leE8ybUZsN0VlZ21ieWlBd0s4RWxVZkhqQVA4NG96TWJxaW…
BridgeBio Pharma (BBIO) Stock Looks Priced At A Premium Despite 148% Returns - Yahoo Finance
<a href="https://news.google.com/rss/articles/CBMinwFBVV95cUxOMTJyNkY5MnZPekVrMGZySWVnWC05VXVwZHVHZkRnNUs0Z3VadmtxVTVIMGNKdWpaSks4d3ZJN0QyQnlxZWtDMkw0Y0pReTVLa016WFMxN3llM3U2X1haOHFDeTJVOTM5Z0VHT3ZaTVQzOHZqdDN6OTRJeF81ZUJQdFVFTmt0MGM0Wm0zZi…
BridgeBio Pharma (BBIO) Stock Looks Fully Priced Despite Strong Sales Growth - simplywall.st
<a href="https://news.google.com/rss/articles/CBMi5AFBVV95cUxPeDFfZ3NXSUJlc1p0Y01veFNKT2d3VGZneEVMdHB5STBwZWI1T2NGSldtN1JjXzVzbGVQOEdoV1JXeFhWMzhCekV1Ml9aM0hIVzFuSmpuWXc1TG5vSmllZ3BYSkRjQ1F2MjJqSmlFV0hDbkZKX1hvbmQ5WGpVS0lUVVpTWldqN3N0SV9JVU…
Data on an investigational drug for children with achondroplasia will be presented in Europe. - Stock Titan
<a href="https://news.google.com/rss/articles/CBMiwAFBVV95cUxOaUV1SG0tOGF0Zlg1WGRiZjdjOFBQUEJCczZBM0VrTDhmSXVuQkxCbU9Ja1BaV1VoQlJObDlQZkJQWHNGcWtCeE5yUXgwU3NHY0N0WmhKVEZoNk5iN29HdUNraVFjYkFLNTNTejJLWVlWQmI3a2M0SVNHY0RGc1RMOXVnS0hfVTV5cEtxTW…
Is BBIO Stock a Buy Now or Too Expensive for the Risk Ahead - Zacks Investment Research
<a href="https://news.google.com/rss/articles/CBMiogFBVV95cUxNcUQtY2lhYmxJNFZLSHhRRzdvb0ZGQmNCc1dKVHNibjB2OTlRcl9xN0VFM2dXWVlaaDlfNVRjeEctWnNLdm1FNHlhd3paUGRpTnNfN0VaX0FaNjJieVAyOHlHSUlsV3E3ZElxQ0hEZWlZR3F0VkxwRFl3UFNJUUZ1dFNuZlNhcGdBQlE4NG…
BridgeBio (BBIO) Stock Looks Fully Priced Despite Fresh Acoramidis Data - Yahoo Finance
<a href="https://news.google.com/rss/articles/CBMingFBVV95cUxPa3drOVZrTUZPTGJaWi1MQXdPemJDUk4weDdlU3BGbjUwZm05SElfWEdRR3RqQWowRHc1N0hhYWNZNXphaFRBZ0MzcEJTSjhwMDh3c0pBUzJxTGJpNGZxdk03VmZRemwzY0tORzZOZTRrTTA5QU96ZUg3MWdfOVFkNDdjRHN5Tms1ZmNON0…
BBIO — Frequently Asked Questions
What is the current share price of BridgeBio Pharma, Inc. (BBIO)?
As of 2026-09-07 16:24 PDT, BridgeBio Pharma, Inc. (BBIO) trades at $74.84 on NasdaqGS. Its 52-week range is $47.29 to $90.17.
What is the market capitalisation of BBIO?
BridgeBio Pharma, Inc. (BBIO) has a market capitalisation of $14.66B on NasdaqGS.
What is the P/E ratio of BBIO?
BBIO trades at a trailing price-to-earnings (P/E) ratio of -20.01. The industry average P/E is 25.17. Its price-to-book (P/B) ratio is -7.26.
What is the return on equity (ROE) of BBIO?
BBIO has a return on equity (ROE) of 34.74%. Its return on capital employed (ROCE) is -77.47%.
Is BBIO a good stock to buy?
This page provides a data-driven analysis of BridgeBio Pharma, Inc. (BBIO), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.